EPO Patent Bulletin: Assays for Diagnosing Fabry Disease Treatment Options
ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Summary
The European Patent Office has published patent application EP4541418A2 concerning assays for diagnosing and evaluating treatment options for Fabry disease. The application lists Amicus Therapeutics, Inc. and the National Institutes of Health as applicants.
What changed
This document is a publication of a European patent application (EP4541418A2) related to assays for diagnosing and evaluating treatment options for Fabry disease. The publication details the applicants (Amicus Therapeutics, Inc., National Institutes of Health) and inventors, along with International Patent Classification codes relevant to diagnostic methods and therapeutic agents.
As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential advancements in diagnostic tools and therapeutic strategies for Fabry disease, which may be of interest to pharmaceutical companies, healthcare providers, and researchers in the field. Compliance officers should note this as a development in the therapeutic landscape for rare diseases.
Source document (simplified)
ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR FABRY DISEASE
Publication EP4541418A2 Kind: A2 Mar 18, 2026
Applicants
Amicus Therapeutics, Inc., NATIONAL INSTITUTES OF HEALTH
Inventors
Lockhart, David, Castelli, Jeff
IPC Classifications
G01N 33/53 20060101AFI20250605BHEP G01N 33/567 20060101ALI20250605BHEP G01N 33/573 20060101ALI20250605BHEP A61K 31/435 20060101ALI20250605BHEP A61K 31/445 20060101ALI20250605BHEP A61K 31/45 20060101ALI20250605BHEP A61P 3/00 20060101ALI20250605BHEP A61P 9/10 20060101ALI20250605BHEP A61P 43/00 20060101ALI20250605BHEP A61P 13/12 20060101ALI20250605BHEP C07D 211/46 20060101ALI20250605BHEP G01N 33/50 20060101ALI20250605BHEP A61K 45/06 20060101ALI20250605BHEP A61P 9/00 20060101ALI20250605BHEP
Designated States
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.